НОВЫЕ ВОЗМОЖНОСТИ ДИАГНОСТИКИ ХРОНИЧЕСКОЙ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ У ПАЦИЕНТОВ С САХАРНЫМ ДИАБЕТОМ 2 ТИПА
https://doi.org/10.20514/2226-6704-2015-0-3-33-39
Abstract
The aim of the study was to examine the plasma concentrations of galectin-3 and brain natriuretic peptide (BNP), indicators of antioxidant protection, oxidative stress, systemic inflammation and endothelial dysfunction, central hemodynamic parameters.
Materials and Methods: The study included patients with CHF without metabolic disturbances (n = 30) and with the combination of heart failure and diabetes mellitus (DM) type 2 (n = 60).
Results: Patients with chronic heart failure, having as co-morbidity of DM have higher levels of biomarkers of heart failure (galectin-3 (R≤0,001), BNP (R≤0,001), as well as more significant changes in hemodynamic parameters. In the group of patients with CHF with preserved ejection fraction (EF) revealed higher levels of galectin-3 (0.955 [0.886; 1,010] ng / ml) compared to patients with reduced ejection fraction (0.816 [0.776; 0.934] ng / ml) (P = 0,01). The level of galectin-3 above 1ng / ml is associated with a poor prognosis for the frequency of hospitalizations in patients with CHF.
About the Authors
А. А. Снеткова
ГБОУ ВПО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова», кафедра поликлинической терапии РФ, г. Москва
Russian Federation
Russian Federation
Н. Ю. Тимофеева
ГБОУ ВПО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова», кафедра поликлинической терапии РФ, г. Москва
Russian Federation
Russian Federation
Т. В. Адашева
ГБОУ ВПО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова», кафедра поликлинической терапии РФ, г. Москва
Russian Federation
Russian Federation
References
1. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр) // Сердечная недостаточность. 2013. Т. 81. № 7. С. 379–472.
2. Braunwald E. N Engl J Med. Biomarkers in heart failure. 2008 May 15;358(20):2148–59.
3. Colak E, Majkić-Singh N, Stanković S, Srecković-Dimitrijević V, Djordjević PB, Lalić K, Lalić N. Parameters of antioxidative defense in type 2 diabetic patients with cardiovascular complications. Ann Med.2005;37(8):613–20.
4. de Boer RA, Lok DJ, Jaarsma T, van der Meer P, Voors AA, Hillege HL, van Veldhuisen DJ. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med. 2011 Feb;43(1):60–68.
5. de Boer RA, Voors AA, Muntendam P, van Gilst WH, van Veldhuisen DJ. Galectin-3: a novel mediator of heart failure development and progression.Eur J HeartFail. 2009 Sep;11(9):811–7.
6. de Boer RA, Yu L, van Veldhuisen DJ. Galectin-3 in cardiac remodeling and heart failure. Curr Heart Fail Rep. 2010 Mar;7(1):1–8.
7. Dei Cas A, Khan SS, Butler J, Mentz RJ, Bonow RO, Avogaro A, Tschoepe D, Doehner W, Greene SJ, Senni M, Gheorghiade M, Fonarow GC. Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure. JACC HeartFail. 2015 Feb;3(2):136–45.
8. Dirk J. A. Lok, Peter Van Der Meer, Pieta W. Bruggink-Andre´ de la Porte, Erik Lipsic, Jan Van Wijngaarden, Hans L. Hillege, Dirk J. van Veldhuisen. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Eur J HeartFail. 2012 Jan;14(1):74–81.
9. Felker GM, Fiuzat M, Shaw LK, Clare R, Whellan DJ, Bettari L, Shirolkar SC, Donahue M, Kitzman DW, Zannad F, Piña IL, O’Connor CM. Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. CircHeartFail. 2012 Jan;5(1):72–8.
10. Jin QH, Lou YF, Li TL, Chen HH, Liu Q, He XJ. Serum galectin-3: a risk factor for vascular complications in type 2 diabetes mellitus. ChinMed J (Engl). 2013;126(11):2109–15.
11. Kroon MH, van den Hurk K, Alssema M, Kamp O, Stehouwer CD, Henry RM, Diamant M, Boomsma F, Nijpels G, Paulus WJ, Dekker JM.. Prospective associations of B-type natriuretic peptide with markers of left ventricular function in individuals with and without type 2 diabetes: an 8-year follow-up of the Hoorn Study. DiabetesCare. 2012 Dec;35(12):2510–4.
12. Lindman BR, Dávila-Román VG, Mann DL, McNulty S, Semigran MJ, Lewis GD, de las Fuentes L, Joseph SM, Vader J, Hernandez AF,Redfield MM. Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study.J AmCollCardiol. 2014 Aug 12;64(6):541–9.
13. McKelvie RS, Komajda M, McMurray J, Zile M, Ptaszynska A, Donovan M,Carson P, Massie BM. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial. J Card Fail 16:128–134.
14. Milting H, Ellinghaus P, Seewald M, et al.: Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices. J Heart Lung Transplant 2008, 27:589–596.
15. Ohkura T, Fujioka Y1, Nakanishi R1, Shiochi H1, Sumi K1, Yamamoto N1, Matsuzawa K2, Izawa S1, Ohkura H2, Ueta E3, Kato M1, Miyoshi E4, Taniguchi S2, Yamamoto K1. Low serum galectin-3 concentrations are associated with insulin resistance in patients with type 2 diabetes mellitus.DiabetolMetabSyndr. 2014 Sep 27;6(1):106.
16. Rauchhaus M, Doehner W, Francis DP, Davos C, Kemp M, Liebenthal C, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation. 2000;102:3060–7.
17. Saksida T, Nikolic I, Vujicic M, Nilsson UJ, Leffler H, Lukic ML, Stojanovic I, Stosic-Grujicic S. Galectin-3 deficiency protects pancreatic islet cells from cytokine-triggered apoptosis in vitro. J Cell Physiol. 2013;228:1568–1576.
18. Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JP, Schroen B, André S, Crijns HJ, Gabius HJ, Maessen J, Pinto YM. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004 Nov 9;110(19):3121–8.
19. Van der Velde AR, Gullestad L, Ueland T, Aukrust P, Guo Y, Adourian A, Muntendam P, van Veldhuisen DJ, de Boer RA. Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH. CircHeartFail. 2013 Mar;6(2):219–26.
20. van Kimmenade RR1, Januzzi JL Jr, Ellinor PT, Sharma UC, Bakker JA, Low AF, Martinez A, Crijns HJ, MacRae CA, Menheere PP, Pinto YM. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J AmCollCardiol. 2006 Sep 19;48(6):1217–24.
21. Wedel H, McMurray JJ, Lindberg M, Wikstrand J, Cleland JG, Cornel JH, et al. CORONA Study Group Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, highsensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide. Eur J Heart Fail. 2009;11:281–91.
Review
For citations:
Снеткова А.А., Тимофеева Н.Ю., Адашева Т.В. НОВЫЕ ВОЗМОЖНОСТИ ДИАГНОСТИКИ ХРОНИЧЕСКОЙ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ У ПАЦИЕНТОВ С САХАРНЫМ ДИАБЕТОМ 2 ТИПА. The Russian Archives of Internal Medicine. 2015;(3):33-39. (In Russ.) https://doi.org/10.20514/2226-6704-2015-0-3-33-39
Views:
788
Email this article 